BR9712256A - Derivados de 2-ciano imino imidazol inibidores da pde iv - Google Patents

Derivados de 2-ciano imino imidazol inibidores da pde iv

Info

Publication number
BR9712256A
BR9712256A BR9712256A BR9712256A BR9712256A BR 9712256 A BR9712256 A BR 9712256A BR 9712256 A BR9712256 A BR 9712256A BR 9712256 A BR9712256 A BR 9712256A BR 9712256 A BR9712256 A BR 9712256A
Authority
BR
Brazil
Prior art keywords
powder
imidazole derivatives
cyano imino
imino
cyano
Prior art date
Application number
BR9712256A
Other languages
English (en)
Other versions
BR9712256B1 (pt
Inventor
Eddy Jean Edgard Freyne
Francisco Javi Fernandez-Gadea
Jose Ignacio Andres-Gil
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9712256A publication Critical patent/BR9712256A/pt
Publication of BR9712256B1 publication Critical patent/BR9712256B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI9712256-4A 1996-10-02 1997-09-24 composto derivado de 2-ciano imino imidazol, processo de preparação do mesmo e composição. BR9712256B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02
PCT/EP1997/005322 WO1998014432A1 (en) 1996-10-02 1997-09-24 Pde iv inhibiting 2-cyanoiminoimidazole derivatives

Publications (2)

Publication Number Publication Date
BR9712256A true BR9712256A (pt) 1999-08-24
BR9712256B1 BR9712256B1 (pt) 2011-04-19

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9712256-4A BR9712256B1 (pt) 1996-10-02 1997-09-24 composto derivado de 2-ciano imino imidazol, processo de preparação do mesmo e composição.

Country Status (31)

Country Link
US (1) US6051718A (pt)
EP (1) EP0934280B1 (pt)
JP (1) JP3068208B2 (pt)
KR (1) KR100520002B1 (pt)
CN (1) CN1106387C (pt)
AR (1) AR008875A1 (pt)
AT (1) ATE236884T1 (pt)
AU (1) AU719561B2 (pt)
BG (1) BG64278B1 (pt)
BR (1) BR9712256B1 (pt)
CA (1) CA2267322C (pt)
CY (1) CY2380B1 (pt)
CZ (1) CZ297474B6 (pt)
DE (1) DE69720757T2 (pt)
DK (1) DK0934280T3 (pt)
EE (1) EE03825B1 (pt)
ES (1) ES2196308T3 (pt)
HK (1) HK1020344A1 (pt)
HU (1) HU225158B1 (pt)
IL (2) IL129298A0 (pt)
MY (1) MY116980A (pt)
NO (1) NO312960B1 (pt)
NZ (1) NZ334971A (pt)
PL (1) PL194673B1 (pt)
PT (1) PT934280E (pt)
RU (1) RU2180902C2 (pt)
SI (1) SI0934280T1 (pt)
SK (1) SK285878B6 (pt)
TR (1) TR199900732T2 (pt)
UA (1) UA62939C2 (pt)
WO (1) WO1998014432A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507022A (en) 1998-04-01 2002-06-28 Janssen Pharmaceutica Nv PDE IV inhibiting pyridine derivatives
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
JP4251872B2 (ja) * 2001-04-19 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−イミノイミダゾール誘導体（２）
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
CN100358514C (zh) * 2001-07-11 2008-01-02 日研化学株式会社 过敏性眼疾病治疗剂
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
CA2469939C (en) 2001-12-14 2012-06-19 Applied Research Systems Ars Holding N.V. Method of inducing ovulation using a non-polypeptide camp level modulator
JP4549970B2 (ja) * 2003-02-19 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 環状ベンズアミジン誘導体の製造方法
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2875964C (en) * 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
WO1994002465A1 (en) * 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
WO1994012461A1 (en) * 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DK0711282T3 (da) * 1993-07-28 2002-09-16 Aventis Pharma Ltd Forbindelser som PDE IV og TNF inhibitorer
WO1995005386A1 (en) * 1993-08-19 1995-02-23 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
MX9700068A (es) * 1994-06-24 1997-12-31 Euro Celtique Sa Compuestos y metodo para inhibir a la fosfodiesterasa iv.
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
IL129298A (en) 2006-04-10
KR100520002B1 (ko) 2005-10-13
SI0934280T1 (en) 2003-12-31
SK285878B6 (sk) 2007-10-04
CA2267322C (en) 2007-11-06
NO991560L (no) 1999-06-02
EE9900112A (et) 1999-10-15
AU4779297A (en) 1998-04-24
CZ102899A3 (cs) 1999-07-14
AU719561B2 (en) 2000-05-11
SK34499A3 (en) 2000-04-10
PT934280E (pt) 2003-08-29
HUP9904063A3 (en) 2000-11-28
BG103220A (en) 1999-11-30
JP3068208B2 (ja) 2000-07-24
RU2180902C2 (ru) 2002-03-27
DE69720757D1 (de) 2003-05-15
ATE236884T1 (de) 2003-04-15
AR008875A1 (es) 2000-02-23
JP2000503678A (ja) 2000-03-28
MY116980A (en) 2004-04-30
WO1998014432A1 (en) 1998-04-09
DE69720757T2 (de) 2004-03-04
CY2380B1 (en) 2004-06-04
ES2196308T3 (es) 2003-12-16
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
HK1020344A1 (en) 2000-04-14
PL332573A1 (en) 1999-09-27
HU225158B1 (en) 2006-07-28
NZ334971A (en) 2000-09-29
NO312960B1 (no) 2002-07-22
DK0934280T3 (da) 2003-07-21
CZ297474B6 (cs) 2006-12-13
CA2267322A1 (en) 1998-04-09
EE03825B1 (et) 2002-08-15
CN1232456A (zh) 1999-10-20
EP0934280A1 (en) 1999-08-11
HUP9904063A2 (hu) 2000-09-28
NO991560D0 (no) 1999-03-30
PL194673B1 (pl) 2007-06-29
BR9712256B1 (pt) 2011-04-19
US6051718A (en) 2000-04-18
CN1106387C (zh) 2003-04-23
IL129298A0 (en) 2000-02-17
BG64278B1 (bg) 2004-08-31
EP0934280B1 (en) 2003-04-09
UA62939C2 (uk) 2004-01-15

Similar Documents

Publication Publication Date Title
BR9712256A (pt) Derivados de 2-ciano imino imidazol inibidores da pde iv
PL337773A1 (en) Derivatives of benzimidazoles
NO20003723D0 (no) Triazol- og imidazolderivater
EP1037639A4 (en) HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
NO995113D0 (no) Substituerte benzopyranderivater for behandling av inflammasjon
IL145508A0 (en) Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
BR9701877A (pt) Derivados de aza-hexano heterocíclicos antiviralmente ativos
DE69713284D1 (de) Triazol-Derivate als Arzneimittel
NO20013945D0 (no) Fremstilling av isoflavonderivater
NO20021690L (no) Benzodiazepin-derivater
NO20021360D0 (no) Regioselektiv syntese av rapamycin-derivater
TR199501561A2 (tr) Imidazol türevleri.
PT1173187E (pt) Preparacoes combinadas compreendendo derivados de antraciclina
ATE375332T1 (de) Imidazol verbindungen und ihre medizinische verwendung
PT1228073E (pt) Compostos de imidazol como inibidores de fosfodiesterase
PL341620A1 (en) Heteroaryl-substituted derivatives of pyrrole, methods of obtaining them and their application
NO20015505L (no) Fremstilling av komplekse karbohydrater
PT1222193E (pt) Derivados de imidazol como inibidores da fosfodiesterase
AU1711499A (en) Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds or inhibition of inflammation
ZA9810558B (en) Imidazole derivatives their preparation and their therapeutic application
ATE241626T1 (de) Kondensierte imidazolderivate als modulatoren vielfacher medikamentenresistenz
EP1152061A4 (en) DEVELOPMENT OF A METHOD FOR SCREENING PHYSIOLOGICALLY ACTIVE DERIVATIVES OF PYRROLE IMIDAZOLE
DE69615023D1 (de) Styrylbenzimidazolderivate als inhibitoren der glatten muskelzellenproliferation
GB2341861B (en) Substituted imidazole derivatives and their use as histamine H3 receptor ligands
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 233/44, A61K 31/00, A61K 31/415, A61K 31/4164, A61K 31/4168, A61P 11/00, A61P 11/06, A61P 29/00, A61P 37/00, A61P 37/08, C07D 233/48, C07D 233/88, C07D 405/12

Ipc: C07D 233/44 (2009.01), A61K 31/00 (2009.01), A61K

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/04/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 19.04.2021